Prashanthi Vemuri

List of Publications by Citations

203 papers	14,201 citations	61 h-index	117 g-index
235 ext. papers	17,828 ext. citations	7.5 avg, IF	6.36 L-index

#	Paper	IF	Citations
203	Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurology, The*, **2013**, 12, 207-16	24.1	2557
202	Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. *Clinical Epidemiology*, **2014**, 6, 37-48	5.9	521
201	An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. *Annals of Neurology*, **2012**, 71, 765-75	9.4	435
200	Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. *Brain*, **2010**, 133, 3336-48	11.2	377
199	Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. *Alzheimer's and Dementia*, **2020**, 16, 1305-1311	1.2	365
198	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 205-216	1.2	358
197	Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. *NeuroImage*, **2008**, 39, 1186-97	7.9	342
196	Non-stationarity in the "resting brain's" modular architecture. *PLoS ONE*, **2012**, 7, e39731	3.7	293
195	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. *Brain*, **2012**, 135, 765-83	11.2	277
194	Cascading network failure across the Alzheimer's disease spectrum. *Brain*, **2016**, 139, 547-62	11.2	265
193	Brain β-amyloid load approaches a plateau. *Neurology*, **2013**, 80, 890-6	6.5	260
192	Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. *Lancet Neurology, The*, **2014**, 13, 997-1005	24.1	246
191	Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. *JAMA Neurology*, **2015**, 72, 511-9	17.2	229
190	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. *Brain*, **2009**, 132, 2932-46	11.2	223
189	Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimer's and Dementia*, **2018**, 14, 989-997	1.2	217
188	Diagnostic neuroimaging across diseases. *NeuroImage*, **2012**, 61, 457-63	7.9	199
187	Longitudinal tau PET in ageing and Alzheimer's disease. *Brain*, **2018**, 141, 1517-1528	11.2	194

168	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. *Alzheimer's Research and Therapy*, **2014**, 6, 1	9	110
167	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. *JAMA Neurology*, **2019**,	17.2	106
166	Sex and gender differences in the causes of dementia: a narrative review. *Maturitas*, **2014**, 79, 196-201	5	103
165	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. *Alzheimer's and Dementia*, **2015**, 11, 740-56	1.2	101
164	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. *Annals of Neurology*, **2017**, 82, 706-718	9.4	99
163	Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. *Brain*, **2011**, 134, 1479-92	11.2	96
162	Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia. *JAMA Neurology*, **2018**, 75, 672-680	17.2	95
161	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. *JAMA Neurology*, **2017**, 74, 718-726	17.2	87
160	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. *Archives of Neurology*, **2012**, 69, 856-67		86
159	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. *Neurobiology of Aging*, **2014**, 35, 2096-106	5.6	85
158	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. *Lancet Neurology, The*, **2016**, 15, 56-64	24.1	82
157	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. *Alzheimer's and Dementia*, **2019**, 15, 205-216	1.2	82
156	Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. *Neurology*, **2019**, 93, e252-e260	6.5	81
155	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. *Brain*, **2019**, 142, 3230-3242	11.2	77
154	Resting state functional MRI in Alzheimer's Disease. *Alzheimer's Research and Therapy*, **2012**, 4, 2	9	76
153	Role of structural MRI in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2010**, 2, 23	9	76
152	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. *NeuroImage*, **2011**, 55, 522-31	7.9	74
151	MRI and MRS predictors of mild cognitive impairment in a population-based sample. *Neurology*, **2013**, 81, 126-33	6.5	71

150	Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier. *NeuroImage*, **2011**, 58, 785-92	7.9	71
149	Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. *Alzheimer's and Dementia*, **2017**, 13, 168-177	1.2	70
148	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. *Neurology*, **2012**, 79, 553-60	6.5	69
147	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. *Neurology*, **2013**, 80, 911-8	6.5	68
146	Identification of Anonymous MRI Research Participants with Face-Recognition Software. *New England Journal of Medicine*, **2019**, 381, 1684-1686	59.2	67
145	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. *Neurobiology of Aging*, **2015**, 36, 1245-52	5.6	64
144	White matter hyperintensities: relationship to amyloid and tau burden. *Brain*, **2019**, 142, 2483-2491	11.2	62
143	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. *Alzheimer's and Dementia*, **2018**, 14, 563-575	1.2	61
142	Association of hypometabolism and amyloid levels in aging, normal subjects. *Neurology*, **2014**, 82, 1959-67	6.5	60
141	A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. *Journal of Neuropathology and Experimental Neurology*, **2012**, 71, 1113-22	3.1	60
140	Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. *JAMA Neurology*, **2013**, 70, 1030-8	17.2	58
139	Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 6, 21-30	5.2	57
138	Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. *Neurology*, **2016**, 86, 1128-35	6.5	55
137	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. *Brain*, **2012**, 135, 2470-7	11.2	53
136	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. *Sleep Medicine*, **2017**, 32, 236-243	4.6	49
135	Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. *NeuroImage*, **2017**, 144, 113-127	7.9	49
134	Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects. *Brain*, **2019**, 142, 1148-1160	11.2	49
133	Progranulin-associated PiB-negative logopenic primary progressive aphasia. *Journal of Neurology*, **2014**, 261, 604-14	5.5	48

#	Reference	IF	Citations
132	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 1005-1014	1.2	47
131	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. *Neurology*, **2013**, 81, 1681-9	6.5	46
130	Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE ɛ4 Genotype. *JAMA Neurology*, **2017**, 74, 332-338	17.2	44
129	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. *Brain*, **2019**, 142, 1134-1147	11.2	44
128	Atrial fibrillation, cognitive impairment, and neuroimaging. *Alzheimer's and Dementia*, **2016**, 12, 391-8	1.2	43
127	Neuroimaging Correlates of Cerebral Microbleeds: The ARIC Study (Atherosclerosis Risk in Communities). *Stroke*, **2017**, 48, 2964-2972	6.7	40
126	Antemortem MRI findings associated with microinfarcts at autopsy. *Neurology*, **2014**, 82, 1951-8	6.5	39
125	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. *Neurology*, **2019**, 93, e29-e39	6.5	36
124	Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging. *Translational Psychiatry*, **2019**, 9, 123	8.6	34
123	Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort. *Alzheimer's and Dementia*, **2016**, 12, 281-91	1.2	34
122	Effects of hormone therapy on brain structure: A randomized controlled trial. *Neurology*, **2016**, 87, 887-96	6.5	33
121	[Formula: see text]Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. *Clinical Neuropsychologist*, **2017**, 31, 99-117	4.4	33
120	Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging. *Journal of the American Geriatrics Society*, **2017**, 65, 792-799	5.6	32
119	Cerebral microbleeds: Prevalence and relationship to amyloid burden. *Neurology*, **2019**, 92, e253-e262	6.5	31
118	The role of cerebrovascular disease when there is concomitant Alzheimer disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 952-6	6.9	30
117	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. *Annals of Neurology*, **2018**, 84, 705-716	9.4	30
116	The Brain in Kidney Disease (BRINK) Cohort Study: Design and Baseline Cognitive Function. *American Journal of Kidney Diseases*, **2016**, 67, 593-600	7.4	29
115	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. *International Psychogeriatrics*, **2018**, 30, 245-251	3.4	28

114	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. *NeuroImage*, **2015**, 113, 61-9	7.9	26
113	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. *Neurology*, **2018**, 90, e466-e473	6.5	26
112	Predicting future rates of tau accumulation on PET. *Brain*, **2020**, 143, 3136-3150	11.2	25
111	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. *JAMA Neurology*, **2021**, 78, 1108-1117	17.2	25
110	Prevalence and Natural History of Superficial Siderosis: A Population-Based Study. *Stroke*, **2017**, 48, 3210-3214	6.7	24
109	Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. *Scientific Reports*, **2019**, 9, 2235	4.9	24
108	A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR. *Journal of Alzheimer's Disease*, **2019**, 67, 181-195	4.3	24
107	Artificial Intelligence-Electrocardiography to Predict Incident Atrial Fibrillation: A Population-Based Study. *Circulation: Arrhythmia and Electrophysiology*, **2020**, 13, e009355	6.4	23
106	Association of Apolipoprotein E e4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. *JAMA Network Open*, **2019**, 2, e1913909	10.4	22
105	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. *NeuroImage*, **2011**, 54, 985-91	7.9	22
104	Joint associations of β-amyloidosis and cortical thickness with cognition. *Neurobiology of Aging*, **2018**, 65, 121-131	5.6	21
103	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. *Neurology*, **2016**, 87, 691-8	6.5	20
102	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. *Annals of Neurology*, **2019**, 86, 866-877	9.4	20
101	Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. *Alzheimer's and Dementia*, **2019**, 15, 1437-1447	1.2	20
100	Cerebral microbleed incidence, relationship to amyloid burden: The Mayo Clinic Study of Aging. *Neurology*, **2020**, 94, e190-e199	6.5	20
99	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. *Journal of Alzheimer's Disease*, **2017**, 55, 1069-1082	4.3	20
98	Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements. *Human Brain Mapping*, **2017**, 38, 3323-3336	5.9	19
97	Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. *JAMA Neurology*, **2015**, 72, 1475-83	17.2	19

96	Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2018**, 73, 1244-1250	6.4	19
95	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. *Alzheimer's and Dementia*, **2014**, 10, 779-89	1.2	19
94	Mechanisms underlying resilience in ageing. *Nature Reviews Neuroscience*, **2019**, 20, 246	13.5	19
93	Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. *Journal of Alzheimer's Disease*, **2018**, 65, 1345-1352	4.3	18
92	Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer's Pathophysiology. *Scientific Reports*, **2020**, 10, 2975	4.9	17
91	[IC-P-122]: THE MAYO CLINIC ADULT LIFE SPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFE SPAN **2017**, 13, P93-P94		17
90	Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72. *Archives of Neurology*, **2012**, 69, 1164-9		16
89	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity: The Mayo Clinic Study of Aging. *Stroke*, **2019**, 50, 3037-3044	6.7	15
88	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. *NeuroImage: Clinical*, **2018**, 19, 939-947	5.3	15
87	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. *Frontiers in Aging Neuroscience*, **2019**, 11, 355	5.3	14
86	Automatic detection of three-dimensional vascular tree centerlines and bifurcations in high-resolution magnetic resonance angiography. *Investigative Radiology*, **2005**, 40, 661-71	10.1	14
85	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. *Neurobiology of Aging*, **2020**, 96, 176-183	5.6	14
84	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. *Neurology*, **2017**, 89, 2039-2048	6.5	13
83	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. *Mayo Clinic Proceedings*, **2020**, 95, 1195-1205	6.4	13
82	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. *Neurology*, **2020**, 94, e1793-e1802	6.5	13
81	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. *Neurobiology of Aging*, **2016**, 46, 32-42	5.6	13
80	The GGGGCC repeat expansion in C9ORF72 in a case with discordant clinical and FDG-PET findings: PET trumps syndrome. *Neurocase*, **2014**, 20, 110-20	0.8	13
79	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. *Neurology*, **2020**, 94, e15-e29	6.5	13

78	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. *NeuroImage*, **2021**, 224, 117433	7.9	13
77	Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. *JAMA Neurology*, **2021**, 78, 217-228	17.2	13
76	"Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game. *Alzheimer's Research and Therapy*, **2018**, 10, 53	9	13
75	Investigation of white matter PiB uptake as a marker of white matter integrity. *Annals of Clinical and Translational Neurology*, **2019**, 6, 678-688	5.3	11
74	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. *Annals of Neurology*, **2020**, 87, 556-567	9.4	11
73	Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging. *Current Opinion in Neurology*, **2016**, 29, 405-11	7.1	11
72	Improving the resistance and resilience framework for aging and dementia studies. *Alzheimer's Research and Therapy*, **2020**, 12, 41	9	11
71	The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2019**, 74, 877-883	6.4	10
70	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 5, 5-14	5.2	9
69	Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. *Journal of the American Geriatrics Society*, **2018**, 66, 2274-2281	5.6	9
68	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. *Alzheimer's and Dementia*, **2021**,	1.2	9
67	Linking Amyloid-β and Tau Deposition in Alzheimer Disease. *JAMA Neurology*, **2017**, 74, 766-768	17.2	8
66	Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults. *Neurology*, **2020**, 94, e1571-e1579	6.5	8
65	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. *Neurocase*, **2016**, 22, 55-9	0.8	8
64	NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages. *Annals of Neurology*, **2021**, 89, 1145-1156	9.4	8
63	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. *NeuroImage*, **2021**, 231, 117845	7.9	8
62	Physical exercise and cognitive engagement outcomes for mild neurocognitive disorder: a group-randomized pilot trial. *Trials*, **2018**, 19, 573	2.8	8
61	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. *Alzheimer's and Dementia*, **2020**, 16, 1013-1022	1.2	7

60	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. *British Journal of Anaesthesia*, **2020**, 124, 594-602	5.4	7
59	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. *British Journal of Anaesthesia*, **2019**, 123, 808-817	5.4	7
58	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. *Alzheimer's and Dementia*, **2021**, 17, 801-812	1.2	7
57	Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition. *Neurology*, **2019**, 93, e2237-e2246	6.5	7
56	Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging. *American Journal of Geriatric Psychiatry*, **2021**, 29, 179-191	6.5	6
55	Association of Hospitalization with Long-Term Cognitive Trajectories in Older Adults. *Journal of the American Geriatrics Society*, **2021**, 69, 660-668	5.6	6
54	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer's pathophysiology. *Acta Neuropathologica Communications*, **2021**, 9, 48	7.3	6
53	Cognitive Impairment and Dementia After Stroke: Design and Rationale for the DISCOVERY Study. *Stroke*, **2021**, 52, e499-e516	6.7	6
52	-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. *Science Translational Medicine*, **2021**, 13, eabc9375	17.5	6
51	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 2431-2436	9.4	5
50	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. *Scientific Reports*, **2018**, 8, 7421	4.9	5
49	Fully bayesian longitudinal unsupervised learning for the assessment and visualization of AD heterogeneity and progression. *Aging*, **2020**, 12, 12622-12647	5.6	5
48	Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12115	5.2	5
47	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. *Alzheimer's and Dementia*, **2021**,	1.2	5
46	Uptake of AV-1451 in meningiomas. *Annals of Nuclear Medicine*, **2017**, 31, 736-743	2.5	4
45	Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging. *Neurobiology of Aging*, **2019**, 79, 43-49	5.6	4
44	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. *Brain Communications*, **2021**, 3, fcab106	4.5	4
43	Association of Cortical and Subcortical β-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia. *Journal of Neuropsychiatry and Clinical Neurosciences*, **2021**, 33, 64-71	2.7	4

42	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. *NeuroImage*, **2021**, 238, 118259	7.9	4
41	Frequency of Acute and Subacute Infarcts in a Population-Based Study. *Mayo Clinic Proceedings*, **2018**, 93, 300-306	6.4	3
40	Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. *Annals of Neurology*, **2021**, 90, 751-762	9.4	3
39	Variants in and are associated with higher tau deposition. *Brain Communications*, **2020**, 2, fcaa159	4.5	3
38	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. *Alzheimer's and Dementia* , **2021**,	1.2	3
37	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. *Brain Communications*, **2021**, 3, fcaa238	4.5	3
36	Stemming the Alzheimer tsunami: introduction to the special issue on reserve and resilience in Alzheimer's disease. *Brain Imaging and Behavior*, **2017**, 11, 301-303	4.1	2
35	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. *Brain Communications*, **2022**, 4, fcac017	4.5	2
34	Imaging Markers of Vascular Brain Health: Quantification, Clinical Implications, and Future Directions.. *Stroke*, **2022**, STROKEAHA120032611	6.7	2
33	H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults.. *Neurobiology of Aging*, **2022**, 112, 16-26	5.6	2
32	Cerebrospinal fluid dynamics and discordant amyloid biomarkers. *Neurobiology of Aging*, **2021**, 110, 27-36	5.6	2
31	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. *Brain Communications*, **2021**, 3, fcab076	4.5	2
30	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. *Journal of Alzheimer's Disease*, **2021**, 81, 113-122	4.3	2
29	Brain MRI after critical care admission: A longitudinal imaging study. *Journal of Critical Care*, **2021**, 62, 117-123	4	2
28	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.. *Alzheimer's Research and Therapy*, **2021**, 13, 199	9	2
27	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. *Journal of Stroke and Cerebrovascular Diseases*, **2019**, 28, 104451	2.8	1
26	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition.. *Acta Neuropathologica Communications*, **2022**, 10, 16	7.3	1
25	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 2785-2793	9.4	1

24	Cerebral Microbleeds: Relationship to Antithrombotic Medications. *Stroke*, **2021**, 52, 2347-2355	6.7	1
23	**2019**,		1
22	Brain amyloid, cortical thickness, and changes in activities of daily living. *Annals of Clinical and Translational Neurology*, **2020**, 7, 474-485	5.3	1
21	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. *Frontiers in Neurology*, **2021**, 12, 615024	4.1	1
20	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-PET Signal. *Neurology*, **2021**, 97, e1799-e1808	6.5	1
19	Relationships between amyloid and tau in an elderly population: An accelerated failure time model. *NeuroImage*, **2021**, 242, 118440	7.9	1
18	Exploring common genetic contributors to neuroprotection from amyloid pathology.. *Brain Communications*, **2022**, 4, fcac066	4.5	1
17	A novel method for causal structure discovery from EHR data and its application to type-2 diabetes mellitus. *Scientific Reports*, **2021**, 11, 21025	4.9	0
16	Chronic Kidney Disease Associated with Worsening White Matter Disease and Ventricular Enlargement. *Journal of Alzheimer's Disease*, **2021**, 83, 1729-1740	4.3	0
15	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging.. *NeuroImage*, **2022**, 251, 119020	7.9	0
14	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. *Acta Neuropathologica*, **2022**, 143, 571	14.3	0
13	Artificial Intelligence-Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts.. *Mayo Clinic Proceedings*, **2022**, 97, 871-880	6.4	0
12	[O4-04-02]: MULTIMODAL IMAGING APPROACH TO UNDERSTAND THE IMPACT OF VASCULAR HEALTH ON BRAIN DIFFUSION, PERFUSION, METABOLISM, AND STRUCTURE **2017**, 13, P1235		
11	IC-P-151: Longitudinal outcomes and profiles of distinct biomarker clusters based on vascular disease, neurodegeneration, and amyloid deposition **2015**, 11, P102-P102		
10	F5-01-03: Better intellectual lifestyle to keep cognitive impairment away **2015**, 11, P303-P304		
9	Association of Performance on the Financial Capacity Instrument Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. *Neurology: Clinical Practice*,10.1212/CPJ.0000000000001157	1.7	
8	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging.. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12269	5.2	
7	Neuroimaging in dementias **2020**, 187-197		

12

List of Publications

6	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. *Journal of Alzheimer's Disease*, **2021**, 81, 533-543	4.3
5	IC-01-01: Predictors of Regional TAU-PET Uptake: Mayo Clinic Study of Aging **2016**, 12, P1-P1	13
4	O2-05-04: Resilience Factors for Amyloid Deposition and Neurodegeneration are Different **2016**, 12, P234-P235	
3	O3-04-01: BIOMARKERS FOR CAPTURING AMYLOID-INDEPENDENT EFFECTS OF VASCULAR HEALTH ON COGNITIVE DECLINE **2019**, 15, P885-P886	
2	Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, e272-e280	6.4
1	PL-05-02: AD BIOMARKER EPIDEMIOLOGY IN THE AGING POPULATION: PREVALENCE, RISK FACTORS, AND OUTCOMES **2018**, 14, P1635-P1635	